Dynavax Technologies Corporation (DVAX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Dynavax Technologies Corporation stock (DVAX) is currently trading at $15.50. Dynavax Technologies Corporation PS ratio (Price-to-Sales) is 5.51. Analyst consensus price target for DVAX is $16.00. WallStSmart rates DVAX as Underperform.
- DVAX PE ratio analysis and historical PE chart
- DVAX PS ratio (Price-to-Sales) history and trend
- DVAX intrinsic value — DCF, Graham Number, EPV models
- DVAX stock price prediction 2025 2026 2027 2028 2029 2030
- DVAX fair value vs current price
- DVAX insider transactions and insider buying
- Is DVAX undervalued or overvalued?
- Dynavax Technologies Corporation financial analysis — revenue, earnings, cash flow
- DVAX Piotroski F-Score and Altman Z-Score
- DVAX analyst price target and Smart Rating
Dynavax Technologies Corporation
📊 No data available
Try selecting a different time range
Smart Analysis
Dynavax Technologies Corporation (DVAX) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in operating margin, eps growth, institutional own.. Concerns around return on equity and profit margin. Mixed signals suggest waiting for clearer direction before acting.
Dynavax Technologies Corporation (DVAX) Key Strengths (3)
Earnings per share surging 69.30% year-over-year
101.55% of shares held by major funds and institutions
Strong operational efficiency: $25 kept per $100 revenue
Supporting Valuation Data
Dynavax Technologies Corporation (DVAX) Areas to Watch (6)
Company is destroying shareholder value
Company is losing money with a negative profit margin
Premium valuation at 5.5x annual revenue
Premium pricing at 3.3x book value
Small-cap company with higher risk but more growth potential
Solid revenue growth at 17.70% per year
Supporting Valuation Data
Dynavax Technologies Corporation (DVAX) Detailed Analysis Report
Overall Assessment
This company scores 45/100 in our Smart Analysis, earning a D+ grade. Out of 9 metrics analyzed, 3 register as strengths (avg 9.3/10) while 6 fall into concern territory (avg 3.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on EPS Growth, Institutional Own., Operating Margin. Profitability is solid with Operating Margin at 24.80%. Growth metrics are encouraging with EPS Growth at 69.30%.
The Bear Case
The primary concerns are Return on Equity, Profit Margin, Price/Sales. Some valuation metrics including Price/Sales (5.51), Price/Book (3.30) suggest expensive pricing. Growth concerns include Revenue Growth at 17.70%, which may limit upside. Profitability pressure is visible in Return on Equity at -7.14%, Profit Margin at -13.10%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -7.14% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 17.70% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Profit Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
DVAX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
DVAX's Price-to-Sales ratio of 5.51x trades at a deep discount to its historical average of 356.49x (18th percentile). The current valuation is 100% below its historical high of 6901x set in Mar 2018, and 258% above its historical low of 1.54x in Mar 2023.
Compare DVAX with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Dynavax Technologies Corporation (DVAX) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Dynavax Technologies Corporation is a strong growth company balancing expansion with improving profitability. Revenue reached 331M with 18% growth year-over-year. The company is currently unprofitable, posting a -13.1% profit margin.
Key Findings
Generating 33M in free cash flow and 34M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -13.1% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Dynavax Technologies Corporation.
Bottom Line
Dynavax Technologies Corporation offers an attractive blend of growth (18% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Dynavax Technologies Corporation(DVAX)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company is headquartered in Emeryville, California.